Cryptic peptides, which are expressed in pancreatic cancer cells, could be promising targets for T-cell therapies that attack pancreatic tumors, according to a new study.

Esophageal cancer starts with subtle symptoms like trouble swallowing, heartburn, and hoarseness, but early detection is ...

Jessica Herrala struggled to swallow. Doctors thought she had bulimia but she had a rare condition kept her from eating and ...

Castle Biosciences has signed an agreement to acquire GI health company Previse, which was developed by specialists at Johns Hopkins University School of Medicine in Baltimore. Previse is focused on ...

“We are excited about joining Castle,” said Daniel Lunz, chief executive officer of Previse. “We look forward to the advancements to care we can make together for patients with GI diseases-our ...

Expected to complement Castle's current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development ...